Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma  Stephen.

Slides:



Advertisements
Similar presentations
SOD1 Integrates Signals from Oxygen and Glucose to Repress Respiration Amit R. Reddi, Valeria C. Culotta Cell Volume 152, Issue 1, Pages (January.
Advertisements

The Cell-Non-Autonomous Nature of Electron Transport Chain-Mediated Longevity Jenni Durieux, Suzanne Wolff, Andrew Dillin Cell Volume 144, Issue 1, Pages.
What We Talk About When We Talk About Fat Evan D. Rosen, Bruce M. Spiegelman Cell Volume 156, Issue 1, Pages (January 2014) DOI: /j.cell
Healthy clocks, healthy body, healthy mind Akhilesh B. Reddy, John S. O’Neill Trends in Cell Biology Volume 20, Issue 1, Pages (January 2010) DOI:
A View to a Kill: The Bacterial Type VI Secretion System Brian T. Ho, Tao G. Dong, John J. Mekalanos Cell Host & Microbe Volume 15, Issue 1, Pages 9-21.
ABO-incompatible kidney transplantation Kota Takahashi, Kazuhide Saito Transplantation Reviews Volume 27, Issue 1, Pages 1-8 (January 2013) DOI: /j.trre
Myc Represses Primitive Endoderm Differentiation in Pluripotent Stem Cells Keriayn N. Smith, Amar M. Singh, Stephen Dalton Cell Stem Cell Volume 7, Issue.
Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled.
Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,
Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group  Fernando Franco Pérez, Javier Lavernia, David Aguiar-Bujanda, José.
Large-Cell Transformation of Mycosis Fungoides Occurring at the Site of Previously Treated Cutaneous B-Cell Lymphoma  Jennifer L. Herrmann, Naveed Sami 
Clinical Lymphoma, Myeloma and Leukemia
The Prognostic Significance of Elevated Levels of Serum Ferritin Before Chemotherapy in Patients With Non-Hodgkin Lymphoma  Kyung Ah Yoh, Ho Sup Lee,
Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management  Jorge E. Cortes, Carlos.
Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group  Fernando Franco Pérez, Javier Lavernia, David Aguiar-Bujanda, José.
VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study 
Nishitha M. Reddy, Olalekan Oluwole, John P. Greer, Brian G
Yuji Nakamoto  Clinical Lymphoma, Myeloma and Leukemia 
Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data  Kathleen Lang,
Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,
The Epidemiology and Clinical Associations of Stroke in Patients With Acute Myeloid Leukemia: A Review of 10,972 Admissions From the 2012 National Inpatient.
Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma,
Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.
Prognostic Nomogram for Overall Survival in Extranodal Natural Killer/T-Cell Lymphoma Patients  Kaiguo Li, Ruyue Wang, Shiting Huang, Xinbin Pan, Hongmin.
Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics  Vincent T. Ma, Philip S. Boonstra,
Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care.
Limited Utility of Surveillance Imaging for Detecting Disease Relapse in Patients With Non-Hodgkin Lymphoma in First Complete Remission  Quoc Truong,
A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B- cell Non-Hodgkin Lymphoma  Pallawi Torka, Priyank Patel, Wei Tan,
Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective,
A Comparison of Clofarabine-based (GCLAC) and Cladribine-based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML  Benyam Muluneh, Kaitlyn Buhlinger,
Subepithelial Corneal Immunoglobulin Deposition as a Manifestation of Multiple Myeloma: A Case Report and Literature Review  Trent P. Wang, Steven G.
Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience  AnnaLynn M. Williams, Andrea M. Baran, Carla Casulo,
Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world.
Interim Functional Imaging Is an Independent Predictor of Progression-free Survival in Advanced Classical Hodgkin Lymphoma – A Real-world Analysis  Moussab.
Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study  Rena Buckstein,
Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell.
Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and.
Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment- resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma  Shumaila.
Genetic Mutations in B-Acute Lymphoblastic Leukemia Among African American and European American Children  Amit Reddy, Ingrid Espinoza, Dana Cole, Jason.
An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma  John M. Burke,
Vertebral Fracture Risk of Multiple Myeloma Assessed by a CT-based Finite Element and Trabecular Structure Analysis  Miyuki Takasu, Yoko Kaichi, Kazuo.
Hemophagocytic Lymphohistiocytosis in a Patient With Multiple Myeloma
Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation  Vijaya.
The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.
Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma 
Clinical Lymphoma, Myeloma and Leukemia
Single-Agent Liposomal All-Trans-Retinoic Acid as Initial Therapy for Acute Promyelocytic Leukemia: 13-Year Follow-Up Data  Preetesh Jain, Hagop Kantarjian,
Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I  Carole B. Miller, Rami S. Komrokji, Ruben A. Mesa,
The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation  Rohtesh S. Mehta, Antonio Di Stasi, Borje S.
Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia  George L. Chen, Hong Liu,
Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides  Francine Foss, Madeleine Duvic, Adam Lerner, Joel Waksman, Sean Whittaker 
Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in.
A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute.
Sorafenib As Monotherapy or in Association With Cytarabine and Clofarabine for the Treatment of Relapsed/Refractory FLT3 ITD-Positive Advanced Acute Myeloid.
A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic.
Madeliene Parrott, Simon Rule, Michael Kelleher, Jayne Wilson 
Rituximab-Based Chemoimmunotherapy Prolongs Survival of Patients With Chronic Lymphocytic Leukemia Independently of the Time of Administration  Julio.
Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single- Institution Experience  Bolanle Gbadamosi, Daniel Ezekwudo, Sanjog Bastola,
Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice  Abdalla Awidi, Salah Abbasi,
Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review  Jill A. Bell, Aaron.
Large-Cell Transformation of Mycosis Fungoides Occurring at the Site of Previously Treated Cutaneous B-Cell Lymphoma  Jennifer L. Herrmann, Naveed Sami 
Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,
Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma.
Clinical Lymphoma, Myeloma and Leukemia
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
Mary Eapen  Biology of Blood and Marrow Transplantation 
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience  Andy I. Chen, Alex McMillan,
Autologous Stem Cell Transplantation for POEMS Syndrome
Presentation transcript:

Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma  Stephen D. Smith, Shruti Gandhy, Ajay K. Gopal, Prathima Reddy, Mazyar Shadman, Brian G. Till, Ryan C. Lynch, Sandra Kanan, Andrew Cowan, Lauren Low, Brian T. Hill  Clinical Lymphoma, Myeloma and Leukemia  Volume 19, Issue 1, Pages 48-52 (January 2019) DOI: 10.1016/j.clml.2018.10.006 Copyright © 2018 Elsevier Inc. Terms and Conditions

Figure 1 PFS and OS Among All 37 Patients Abbreviations: OS = Overall survival; PFS = progression-free survival. Clinical Lymphoma, Myeloma and Leukemia 2019 19, 48-52DOI: (10.1016/j.clml.2018.10.006) Copyright © 2018 Elsevier Inc. Terms and Conditions

Figure 2 PFS by High-Risk Mipi-C Versus Other Abbreviations: MIPI = Mantle Cell Lymphoma International Prognostic Index; PFS = progression-free survival. Clinical Lymphoma, Myeloma and Leukemia 2019 19, 48-52DOI: (10.1016/j.clml.2018.10.006) Copyright © 2018 Elsevier Inc. Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.